JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoffmann, I. S.
Right arrow Articles by Cubeddu, L. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoffmann, I. S.
Right arrow Articles by Cubeddu, L. X.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*APOMORPHINE
*CARBACHOL CHLORIDE
*DOPAMINE
*PHYSOSTIGMINE

Differential effects of muscarinic receptor agonists and phorbol ester on muscarinic and D2-dopamine release-modulatory receptors

IS Hoffmann, RK Talmaciu, R Aquino and LX Cubeddu

Department of Pharmacology, School of Pharmacy, Central University of Venezuela, Caracas, Venezuela.

The interaction between an active phorbol ester, 4-beta-phobol-12,13- dibutyrate (PDBu), and muscarinic cholinergic receptor (MAChR) agonists on the electrically evoked neurotransmitter release was studied in the striatal and prefrontal cortex (PFC) of the rabbit. MAChR agonists (carbachol and oxotremorine), physostigmine and PDBu enhanced dopamine (DA) release from striatum and prefrontal cortex. Pretreatment with PDBu antagonized the increase in DA release produced by MAChR agonists (M1 receptors). Pretreatment with MAChR agonists and physostigmine also inhibited the action of PDBu on DA release. The inhibition of ACh release from the striatum induced by MAChR agonists (M2 receptors) and by apomorphine (D2-DA receptors) was antagonized by PDBu. MAChR agonists, however, did not antagonize the effects of the D2 agonist on ACh release. In the prefrontal cortex, PDBu produced greater facilitation of DA release than in the striatum, and MAChR agonists were less effective in inhibiting the effects of PDBu on DA release. This study suggests that the facilitation of DA release induced by the MAChR agonists and that induced by PDBu occur via a similar mechanism: stimulation of protein kinase C. PDBu induces a broad-spectrum loss of responsiveness to M1-MAChR and M2-MAChR and to D2-DA release-modulatory receptors, which is probably due to massive protein kinase C stimulation, signaling cell overstimulation. MAChR agonists, on the other hand, would stimulate the protein kinase C in close proximity to the M1 ACh receptor, facilitating DA release but failing to induce broad-spectrum desensitization.

Volume 278, Issue 2, pp. 662-668, 08/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics.